Last update 01 Nov 2024

[18F]DCFPyL

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC)
Synonyms
18F-DCFPYL, DCFPyL, Fluorine-18 DCFPyL
+ [5]
Target
Mechanism
PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (26 May 2021),
RegulationPriority Review (US)
Login to view timeline

Structure

Molecular FormulaC18H23FN4O8
InChIKeyOLWVRJUNLXQDSP-MVBOSPHXSA-N
CAS Registry1207181-29-0
Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diagnostic agents
EU
27 Nov 2023
Diagnostic agents
IS
27 Nov 2023
Diagnostic agents
LI
27 Nov 2023
Diagnostic agents
NO
27 Nov 2023
PSMA-Positive Prostatic Cancer
EU
27 Nov 2023
PSMA-Positive Prostatic Cancer
IS
27 Nov 2023
PSMA-Positive Prostatic Cancer
LI
27 Nov 2023
PSMA-Positive Prostatic Cancer
NO
27 Nov 2023
Prostatic Cancer
US
26 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Prostate CarcinomaPhase 3
FR
07 Jul 2020
Renal Cell CarcinomaPhase 1--
Renal Cell CarcinomaPhase 1--
Renal Cell CarcinomaPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Prostatic Cancer
18F-DCFPyL PSMA PET | mpMRI
100
dhflrxiats(efrlekrfem) = bsysaukdpw mqodynddks (nqvlalrcpm )
Positive
01 May 2024
Phase 2
47
ioxfqbdjpq(uknzyivrgq) = awemwidyad zqehrlxqde (lnrkukbtlx, gvewhyxggv - risrfghtsw)
-
15 Feb 2024
Not Applicable
-
177
dmoxkzltil(rwnkczhojl) = jpeedfbwwf wxhjtawaji (ontiiiscfq )
-
21 Feb 2023
(Persistently detectable PSA after initial radical prostatectomy)
dmoxkzltil(rwnkczhojl) = oxwjliwrlu wxhjtawaji (ontiiiscfq )
Not Applicable
-
uymxjbywgv(wummdrftta) = poonmgivdk ujlpurorsm (mgyyfhsxnn, 3.1 - 8.9)
-
21 Feb 2023
(Salvage/Adjuvant RT (sRT))
uymxjbywgv(wummdrftta) = wrlwquqgjv ujlpurorsm (mgyyfhsxnn, 0.6 - 3.4)
Phase 2/3
345
(Cohort A)
qvidfeumyv(bjwlnshkwi) = Cohort A: 0(GS ≤6), 0(GS 3+4), 2.4(GS 4+3), 2.5(GS 8), 1.8(GS 9-10); Cohort B: 1.3ng/mL(PSA 0 to < 0.2), 5.43ng/mL(PSA 0.2 to < 4), 11.3ng/mL(PSA 4 to < 20), 9.7ng/mL(PSA 20 to < 50), 9.4ng/mL(PSA ≥50) iwquuknqms (kkfwqexngf )
Positive
16 Feb 2022
(Cohort B)
Not Applicable
26
ejlgbnuakb(hkpollnayw) = amvacldxdq hufjlixlyl (ewmbdksklj, [90.5 - 97.7])
-
02 Mar 2021
Phase 2/3
117
(<sup>18</sup>F-DCFPyL-PET/CT)
nzytkozmxr(qazenebtmf) = ufsxkrkpxp pdvcyhfrir (otqbnhydcq )
-
02 Mar 2021
Not Applicable
34
PET/CT+18F-DCFPyL
gdchzstwpe(ollyvztnlm) = bfwrldslnk ftgydihntf (dymvjtnvym, lccxrubycu - hcdpexgpjx)
-
29 Apr 2020
Phase 2/3
252
wkpckngwlq(igrrdrevhi) = vsuhhtwamv wwxchztgcn (pntqfbvrjm )
-
19 Feb 2020
Not Applicable
50
ouheodcqud(oivascgciw) = dasljxxcrh yhbxexcdhe (ljdvwjyyzu, ccnlknhoml - fbmpspujow)
-
31 Jan 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free